FDA approves 2nd CAR-T cell therapy, this one for certain type of lymphoma

19 October 2017
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration yesterday approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

Yescarta, developed by Kite Pharma, which is now a subsidiary of US biotech giant Gilead Sciences (Nasdaq: GILD) following its $11.9 billion acquisition this year, is a chimeric antigen receptor (CAR) T cell therapy. It is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).

The approval was widely expected, but Gilead’s shares nevertheless edged up 2.8% to $80.01 (having hit $81.60 at one point) in after-hours trading yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology